2020 Q2 Form 10-Q Financial Statement
#000143774920016075 Filed on July 30, 2020
Income Statement
Concept | 2020 Q2 | 2019 Q2 | 2019 Q1 |
---|---|---|---|
Revenue | $1.466M | $2.319M | $1.840M |
YoY Change | -36.78% | 12.68% | 1.71% |
Cost Of Revenue | $1.107M | $1.599M | $1.467M |
YoY Change | -30.77% | -26.28% | 3.67% |
Gross Profit | $359.0K | $720.0K | $373.0K |
YoY Change | -50.14% | -748.65% | -5.33% |
Gross Profit Margin | 24.49% | 31.05% | 20.27% |
Selling, General & Admin | $2.654M | $4.091M | $3.986M |
YoY Change | -35.13% | -7.94% | -11.42% |
% of Gross Profit | 739.28% | 568.19% | 1068.63% |
Research & Development | $1.297M | $1.335M | $1.414M |
YoY Change | -2.85% | 15.19% | -20.43% |
% of Gross Profit | 361.28% | 185.42% | 379.09% |
Depreciation & Amortization | $220.0K | $230.0K | $200.0K |
YoY Change | -4.35% | -4.17% | -27.8% |
% of Gross Profit | 61.28% | 31.94% | 53.62% |
Operating Expenses | $3.951M | $5.426M | $5.400M |
YoY Change | -27.18% | -3.16% | -13.97% |
Operating Profit | -$3.592M | -$4.706M | -$5.027M |
YoY Change | -23.67% | -17.64% | -14.55% |
Interest Expense | $414.0K | $364.0K | $350.0K |
YoY Change | 13.74% | 0.55% | -92.51% |
% of Operating Profit | |||
Other Income/Expense, Net | $4.000K | $329.0K | $240.0K |
YoY Change | -98.78% | 44.93% | -0.41% |
Pretax Income | -$4.000M | -$4.650M | -$5.060M |
YoY Change | -13.98% | -19.83% | -50.78% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$4.000M | -$4.651M | -$5.055M |
YoY Change | -14.0% | -19.8% | -50.83% |
Net Earnings / Revenue | -272.85% | -200.56% | -274.73% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$146.5K | -$728.8K | -$1.191M |
COMMON SHARES | |||
Basic Shares Outstanding | 64.20M | 42.30M | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2020 Q2 | 2019 Q2 | 2019 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $16.55M | $14.75M | $16.71M |
YoY Change | 12.2% | 45.46% | 15.88% |
Cash & Equivalents | $16.55M | $14.75M | $16.71M |
Short-Term Investments | |||
Other Short-Term Assets | $900.0K | $760.0K | $2.340M |
YoY Change | 18.42% | -29.63% | 101.72% |
Inventory | $4.157M | $4.105M | $3.955M |
Prepaid Expenses | |||
Receivables | $1.076M | $1.210M | $1.112M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $22.68M | $20.83M | $24.11M |
YoY Change | 8.88% | 25.88% | 15.15% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.140M | $2.006M | $2.140M |
YoY Change | -43.17% | -4.48% | -11.93% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $594.0K | $384.0K | |
YoY Change | 54.69% | -33.79% | |
Total Long-Term Assets | $6.202M | $7.986M | $2.140M |
YoY Change | -22.34% | 197.99% | -29.14% |
TOTAL ASSETS | |||
Total Short-Term Assets | $22.68M | $20.83M | $24.11M |
Total Long-Term Assets | $6.202M | $7.986M | $2.140M |
Total Assets | $28.88M | $28.82M | $26.25M |
YoY Change | 0.23% | 49.86% | 9.57% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $924.0K | $1.086M | $969.0K |
YoY Change | -14.92% | -20.73% | -55.14% |
Accrued Expenses | $730.0K | $776.0K | $906.0K |
YoY Change | -5.93% | -61.39% | -51.29% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | $10.81M | $8.200M | $7.840M |
YoY Change | 31.83% | 4.86% | 4.26% |
Total Short-Term Liabilities | $16.31M | $14.36M | $12.94M |
YoY Change | 13.63% | 15.3% | 8.25% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $1.300M | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $19.00K | $11.00K | $38.00K |
YoY Change | 72.73% | -94.21% | -65.45% |
Total Long-Term Liabilities | $19.00K | $11.00K | $38.00K |
YoY Change | 72.73% | -94.21% | -65.45% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $16.31M | $14.36M | $12.94M |
Total Long-Term Liabilities | $19.00K | $11.00K | $38.00K |
Total Liabilities | $21.34M | $18.90M | $12.97M |
YoY Change | 12.89% | 49.52% | 7.58% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$358.2M | -$338.6M | -$333.9M |
YoY Change | 5.79% | ||
Common Stock | $365.7M | $348.5M | $347.2M |
YoY Change | 4.94% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $7.549M | $9.920M | $13.28M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $28.88M | $28.82M | $26.25M |
YoY Change | 0.23% | 49.86% | 9.57% |
Cashflow Statement
Concept | 2020 Q2 | 2019 Q2 | 2019 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$4.000M | -$4.651M | -$5.055M |
YoY Change | -14.0% | -19.8% | -50.83% |
Depreciation, Depletion And Amortization | $220.0K | $230.0K | $200.0K |
YoY Change | -4.35% | -4.17% | -27.8% |
Cash From Operating Activities | -$3.430M | -$3.620M | -$5.996M |
YoY Change | -5.25% | -19.02% | -12.81% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | -$10.00K | $83.00K |
YoY Change | -100.0% | -92.31% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $0.00 | $0.00 | $20.00K |
YoY Change | -60.0% | ||
Cash From Investing Activities | $0.00 | $0.00 | -$65.00K |
YoY Change | -100.0% | -241.3% | |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 10.11M | 1.670M | 6.358M |
YoY Change | 505.39% | 351.35% | -59.91% |
NET CHANGE | |||
Cash From Operating Activities | -3.430M | -3.620M | -5.996M |
Cash From Investing Activities | 0.000 | 0.000 | -65.00K |
Cash From Financing Activities | 10.11M | 1.670M | 6.358M |
Net Change In Cash | 6.680M | -1.950M | 297.0K |
YoY Change | -442.56% | -54.44% | -96.71% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$3.430M | -$3.620M | -$5.996M |
Capital Expenditures | $0.00 | -$10.00K | $83.00K |
Free Cash Flow | -$3.430M | -$3.610M | -$6.079M |
YoY Change | -4.99% | -16.82% | -11.6% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2020Q1 | avgr |
Debt Instrument Covenant Compliance Target Minimum Revenue Second Year
DebtInstrumentCovenantComplianceTargetMinimumRevenueSecondYear
|
12000000 | |
avgr |
Change In Rightofuse Asset
ChangeInRightofuseAsset
|
-179000 | ||
CY2015Q3 | avgr |
Debt Instrument Covenant Compliance Cash And Certain Cash Equivalents Minimum
DebtInstrumentCovenantComplianceCashAndCertainCashEquivalentsMinimum
|
3500000 | |
CY2015Q3 | avgr |
Debt Instrument Covenant Compliance Prepayment Multiplier For Revenue Shortfall
DebtInstrumentCovenantCompliancePrepaymentMultiplierForRevenueShortfall
|
2 | |
CY2020Q1 | avgr |
Debt Instrument Covenant Compliance Target Minimum Revenue Next Twelve Months
DebtInstrumentCovenantComplianceTargetMinimumRevenueNextTwelveMonths
|
10000000 | |
avgr |
Accretion Of Preferred Stock Dividends
AccretionOfPreferredStockDividends
|
1934000 | ||
avgr |
Accretion Of Preferred Stock Dividends
AccretionOfPreferredStockDividends
|
1790000 | ||
avgr |
Change In Rightofuse Asset
ChangeInRightofuseAsset
|
86000 | ||
CY2020Q1 | avgr |
Debt Instrument Covenant Compliance Target Minimum Revenue Third Year
DebtInstrumentCovenantComplianceTargetMinimumRevenueThirdYear
|
15000000 | |
CY2015Q3 | avgr |
Debt Instrument Final Facility Fee Percentage
DebtInstrumentFinalFacilityFeePercentage
|
0.15 | |
CY2015Q3 | avgr |
Debt Instrument Financing Fee Percentage
DebtInstrumentFinancingFeePercentage
|
0.015 | |
CY2015Q3 | avgr |
Debt Instrument Redemption Annual Decline In Prepayment Premium Percentage
DebtInstrumentRedemptionAnnualDeclineInPrepaymentPremiumPercentage
|
0.01 | |
CY2015Q3 | avgr |
Debt Instrument Redemption Initial Prepayment Premium Percentage
DebtInstrumentRedemptionInitialPrepaymentPremiumPercentage
|
0.05 | |
CY2015Q3 | avgr |
Debt Instrument Redemption Prepayment Premium Percentage After Fifth Year
DebtInstrumentRedemptionPrepaymentPremiumPercentageAfterFifthYear
|
0 | |
avgr |
Noncash Interest Expense Income And Other Charges Net
NoncashInterestExpenseIncomeAndOtherChargesNet
|
728000 | ||
avgr |
Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs
ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts
|
|||
avgr |
Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan
ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan
|
36000 | ||
avgr |
Noncash Interest Expense Income And Other Charges Net
NoncashInterestExpenseIncomeAndOtherChargesNet
|
629000 | ||
CY2020Q2 | avgr |
Operating Lease Expense Excluding Maintenance Fee And Other Expense Monthly
OperatingLeaseExpenseExcludingMaintenanceFeeAndOtherExpenseMonthly
|
105000 | |
CY2019Q2 | avgr |
Product Warranty Accrual Payments And Release
ProductWarrantyAccrualPaymentsAndRelease
|
25000 | |
avgr |
Product Warranty Accrual Payments And Release
ProductWarrantyAccrualPaymentsAndRelease
|
105000 | ||
avgr |
Product Warranty Accrual Payments And Release
ProductWarrantyAccrualPaymentsAndRelease
|
93000 | ||
CY2018Q1 | avgr |
Proceeds From Issuance Or Sale Of Equity Net
ProceedsFromIssuanceOrSaleOfEquityNet
|
15500000 | |
avgr |
Proceeds From The Issuance Of Common Stock And Convertible Preferred Stock Net Of Issuance Costs
ProceedsFromTheIssuanceOfCommonStockAndConvertiblePreferredStockNetOfIssuanceCosts
|
11636000 | ||
us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
776000 | ||
avgr |
Proceeds From The Issuance Of Common Stock Under Officers And Directors Purchase Plan
ProceedsFromTheIssuanceOfCommonStockUnderOfficersAndDirectorsPurchasePlan
|
36000 | ||
CY2020Q2 | avgr |
Product Warranty Accrual Payments And Release
ProductWarrantyAccrualPaymentsAndRelease
|
50000 | |
CY2020Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
325000 | |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
325000 | |
avgr |
Reclassification Of Right Of Use Asset To Prepaid Rent
ReclassificationOfRightOfUseAssetToPrepaidRent
|
-86000 | ||
avgr |
Reclassification Of Right Of Use Asset To Prepaid Rent
ReclassificationOfRightOfUseAssetToPrepaidRent
|
179000 | ||
CY2019Q2 | avgr |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
1653000 | |
avgr |
Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
|
7993000 | ||
avgr |
Transfer Between Inventories And Property And Equipment
TransferBetweenInventoriesAndPropertyAndEquipment
|
-32000 | ||
avgr |
Transfer Between Inventories And Property And Equipment
TransferBetweenInventoriesAndPropertyAndEquipment
|
287000 | ||
avgr |
Warranty Period
WarrantyPeriod
|
P1Y | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1009000 | ||
CY2020Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
924000 | |
CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
663000 | |
CY2020Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1076000 | |
CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1458000 | |
CY2020Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
730000 | |
CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
654000 | |
CY2020Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
365684000 | |
CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
355220000 | |
CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
|
895000 | |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
|
967000 | |
us-gaap |
Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
|
1790000 | ||
us-gaap |
Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
|
1934000 | ||
CY2019Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
516000 | |
CY2019Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
516000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
776000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1009000 | ||
CY2020Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
19000 | |
CY2019Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
19000 | |
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
84000 | ||
us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
86000 | ||
CY2020Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3649439 | |
CY2019Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3141838 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3666451 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3987225 | ||
CY2020Q2 | us-gaap |
Assets
Assets
|
28884000 | |
CY2019Q4 | us-gaap |
Assets
Assets
|
23825000 | |
CY2020Q2 | us-gaap |
Assets Current
AssetsCurrent
|
22682000 | |
CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
16624000 | |
CY2019Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
|
0 | |
CY2020Q2 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
|
0 | |
CY2020Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16550000 | |
CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
10943000 | |
CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16410000 | |
CY2019Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14754000 | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
5607000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1656000 | ||
CY2019Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
2753999 | |
CY2020Q2 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
2753999 | |
CY2020Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
27539986 | |
CY2020Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2020Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2020Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
51339024 | |
CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
10364663 | |
CY2020Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
51339024 | |
CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
10364663 | |
CY2020Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
51000 | |
CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
10000 | |
CY2020Q2 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1107000 | |
CY2019Q2 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
1599000 | |
us-gaap |
Cost Of Revenue
CostOfRevenue
|
2867000 | ||
us-gaap |
Cost Of Revenue
CostOfRevenue
|
3066000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
453000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
428000 | ||
CY2020Q2 | us-gaap |
Dividends Payable Current
DividendsPayableCurrent
|
1934000 | |
CY2019Q4 | us-gaap |
Dividends Payable Current
DividendsPayableCurrent
|
||
CY2020Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.18 | |
CY2019Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.87 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.56 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.16 | ||
CY2020Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1151000 | |
CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1782000 | |
us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
CY2020Q2 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
CY2019Q2 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | |
us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
172000 | ||
CY2019Q2 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.065 | |
CY2020Q2 | us-gaap |
Gross Profit
GrossProfit
|
359000 | |
CY2019Q2 | us-gaap |
Gross Profit
GrossProfit
|
720000 | |
us-gaap |
Gross Profit
GrossProfit
|
860000 | ||
us-gaap |
Gross Profit
GrossProfit
|
1093000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
261000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-62000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-382000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
56000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
76000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-673000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-631000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
242000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
465000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1066000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-4000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
|||
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
10000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-30000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
532000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
334000 | ||
CY2020Q2 | us-gaap |
Interest Expense
InterestExpense
|
414000 | |
CY2019Q2 | us-gaap |
Interest Expense
InterestExpense
|
364000 | |
us-gaap |
Interest Expense
InterestExpense
|
812000 | ||
us-gaap |
Interest Expense
InterestExpense
|
714000 | ||
CY2020Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1715000 | |
CY2019Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
1890000 | |
CY2020Q2 | us-gaap |
Inventory Net
InventoryNet
|
4157000 | |
CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
3912000 | |
CY2020Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
2040000 | |
CY2019Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1426000 | |
CY2020Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
402000 | |
CY2019Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
596000 | |
us-gaap |
Inventory Write Down
InventoryWriteDown
|
253000 | ||
us-gaap |
Inventory Write Down
InventoryWriteDown
|
97000 | ||
CY2020Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | |
CY2019Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
90000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
32000 | ||
CY2020Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4468000 | |
CY2020Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
314000 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
628000 | ||
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
806000 | ||
CY2019Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
5800000 | |
CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
5170000 | |
CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1138000 | |
CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1203000 | |
CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
1162000 | |
CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1123000 | |
CY2020Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
702000 | |
CY2019Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P5Y | |
CY2020Q2 | us-gaap |
Liabilities
Liabilities
|
21335000 | |
CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
16930000 | |
CY2020Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
28884000 | |
CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
23825000 | |
CY2020Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16312000 | |
CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12788000 | |
CY2015Q3 | us-gaap |
Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
|
50000000 | |
CY2020Q2 | us-gaap |
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
544000 | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div> Organization</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Organization, Nature of Business</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Avinger, Inc. (the “Company”), a Delaware corporation, was incorporated in <div style="display: inline; font-style: italic; font: inherit;"> March </div><div style="display: inline; font-style: italic; font: inherit;">2007.</div> The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (“PAD”). Patients with PAD have a build-up of plaque in the arteries that supply blood to areas away from the heart, particularly the pelvis and legs. The Company manufactures and sells a suite of products in the United States (“U.S.”) and in select international markets. The Company has developed its Lumivascular platform, which integrates optical coherence tomography (<div style="display: inline; font-style: italic; font: inherit;"> “OCT”) </div>visualization with interventional catheters and is the industry's only system that provides real-time intravascular imaging during the treatment portion of PAD procedures. The Company's Lumivascular platform consists of a capital component, Lightbox, as well as a variety of disposable catheter products. The Company's current products include its non-imaging catheters, Wildcat and Kittycat, as well as its Lumivascular platform products, Ocelot, Ocelot PIXL and Ocelot MVRX, all of which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (“CTO”). The Company also has image-guided atherectomy systems under its suite of Lumivascular products, Pantheris and Pantheris SV, which are designed to allow physicians to precisely remove arterial plaque in PAD patients. The Company is located in Redwood City, California.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Liquidity Matters</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2014</div>-<div style="display: inline; font-style: italic; font: inherit;">15,</div> <div style="display: inline; font-style: italic;">Presentation of Financial Statements - Going Concern (Subtopic <div style="display: inline; font-style: italic; font: inherit;">205</div>-<div style="display: inline; font-style: italic; font: inherit;">40</div>)</div> requires the Company to make certain disclosures if it concludes that there is substantial doubt about the entity's ability to continue as a going concern within <div style="display: inline; font-style: italic; font: inherit;">one</div> year from the date of the issuance of these financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">In the course of its activities, the Company has incurred losses and negative cash flows from operations since its inception. As of <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020, </div>the Company had an accumulated deficit of <div style="display: inline; font-style: italic; font: inherit;">$358.2</div> million. The Company expects to incur losses for the foreseeable future. The Company believes that its cash and cash equivalents of <div style="display: inline; font-style: italic; font: inherit;">$16.6</div> million at <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020 </div>and expected revenues and funds from operations will be sufficient to allow the Company to fund its current operations through at least the <div style="display: inline; font-style: italic; font: inherit;">second</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2021.</div> Even though we received net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$5.5</div> million from the sale of our common stock in <div style="display: inline; font-style: italic; font: inherit;"> June </div>and <div style="display: inline; font-style: italic; font: inherit;"> July 2020, </div><div style="display: inline; font-style: italic; font: inherit;">$3.0</div> million from the sale of our common stock in <div style="display: inline; font-style: italic; font: inherit;"> April </div>and <div style="display: inline; font-style: italic; font: inherit;"> May 2020, </div><div style="display: inline; font-style: italic; font: inherit;">$2.3</div> million of loan proceeds pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security (“CARES”) Act, <div style="display: inline; font-style: italic; font: inherit;">$3.9</div> million from the sale of our common stock in our <div style="display: inline; font-style: italic; font: inherit;"> January 2020 </div>offering, net proceeds of <div style="display: inline; font-style: italic; font: inherit;">$3.8</div> million from the sales of our common stock in our <div style="display: inline; font-style: italic; font: inherit;"> August 2019 </div>offering, and proceeds of <div style="display: inline; font-style: italic; font: inherit;">$8</div> million from the issuance of common stock upon the exercise of warrants during <div style="display: inline; font-style: italic; font: inherit;"> April </div>and <div style="display: inline; font-style: italic; font: inherit;"> May </div>of <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company will need to raise additional funds through future equity or debt financings within the next <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months to meet its operational needs and capital requirements for product development, clinical trials and commercialization and <div style="display: inline; font-style: italic; font: inherit;"> may </div>subsequently require additional fundraising.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company can provide <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that it will be successful in raising funds pursuant to additional equity or debt financings or that such funds will be raised at prices that do <div style="display: inline; font-style: italic; font: inherit;">not</div> create substantial dilution for our existing stockholders. Given the recent decline in the Company's stock price, any financing that we undertake in the next <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months could cause substantial dilution to our existing stockholders, there can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations. In addition, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic and responses thereto have resulted in reduced consumer and investor confidence, instability in the credit and financial markets, volatile corporate profits, and reduced business and consumer spending, which could increase the cost of capital and/or limit the availability of capital to the Company. During the <div style="display: inline; font-style: italic; font: inherit;">second</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020</div> we took certain actions to manage available cash and other resources to mitigate the effects of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> on our business, which included reduction of discretionary costs, reduction of base salaries for all of our non-manufacturing employees by <div style="display: inline; font-style: italic; font: inherit;">20%</div> and reduction of hours worked by our manufacturing workers by <div style="display: inline; font-style: italic; font: inherit;">20%.</div> While some measures such as salaries and hours worked have largely returned to prior levels in <div style="display: inline; font-style: italic; font: inherit;"> July 2020, </div>we will continue to employ certain actions to manage our resources in the foreseeable future. There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that such strategies will be successful in mitigating the negative impacts of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on our business. These conditions raise substantial doubt about the Company's ability to continue as a going concern. If the Company is unable to raise additional capital in sufficient amounts or on terms acceptable to it, the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>have to significantly reduce its operations or delay, scale back or discontinue the development of <div style="display: inline; font-style: italic; font: inherit;">one</div> or more of its products. The financial statements do <div style="display: inline; font-style: italic; font: inherit;">not</div> include any adjustments that might result from the outcome of this uncertainty. The Company's ultimate success will largely depend on its continued development of innovative medical technologies, its ability to successfully commercialize its products and its ability to raise significant additional funding. </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Additionally, due to the substantial doubt about the Company's ability to continue operating as a going concern and the material adverse change clause in the Loan Agreement with CRG Partners III L.P. and certain of its affiliated funds (collectively “CRG”), the entire amount of borrowings at <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>has been classified as current in these financial statements. CRG has <div style="display: inline; font-style: italic; font: inherit;">not</div> invoked the material adverse change clause. </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Public Offerings</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> August 26, 2019, </div>we completed a public offering of <div style="display: inline; font-style: italic; font: inherit;">3,813,559</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font: inherit;">$1.18</div> per share. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$3.8</div> million after underwriting discounts, commissions, legal and accounting fees and the conversion price of the outstanding shares of Series B preferred stock, issued in our <div style="display: inline; font-style: italic; font: inherit;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font: inherit;">$1.18</div> per share as a result. </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 31, 2020, </div>we completed a public offering of <div style="display: inline; font-style: italic; font: inherit;">6,428,572</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font: inherit;">$0.70</div> per share. As a result, we received net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$3.9</div> million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our <div style="display: inline; font-style: italic; font: inherit;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font: inherit;">$0.70</div> per share.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> April 30, 2020, </div>we completed a public offering of <div style="display: inline; font-style: italic; font: inherit;">12,600,000</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font: inherit;">$0.25</div> per share. On <div style="display: inline; font-style: italic; font: inherit;"> May 6, 2020 </div>we issued an additional <div style="display: inline; font-style: italic; font: inherit;">1,890,000</div> shares of common stock at the same offering price pursuant to the exercise in full of the underwriter's over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$3.0</div> million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses. Due to anti-dilution provisions, the conversion price of the outstanding shares of Series B preferred stock, which was issued in our <div style="display: inline; font-style: italic; font: inherit;"> February 2018 </div>offering, was reduced to <div style="display: inline; font-style: italic; font: inherit;">$0.25</div> per share.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> June 26, 2020, </div>we completed a public offering of <div style="display: inline; font-style: italic; font: inherit;">20,000,000</div> shares of common stock at an offering price of <div style="display: inline; font-style: italic; font: inherit;">$0.27</div> per share. On <div style="display: inline; font-style: italic; font: inherit;"> July 9, 2020 </div>we issued an additional <div style="display: inline; font-style: italic; font: inherit;">3,000,000</div> shares of common stock at the same offering price pursuant to the exercise in full of the underwriter's over-allotment option in connection with the aforementioned offering. As a result, we received aggregate net proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$5.5</div> million after underwriting discounts, commissions, legal and accounting fees, and other ancillary expenses.</div></div> | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
14002000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
8029000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
|||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-70000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8395000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9615000 | ||
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4000000 | |
CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4651000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-9851000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-9706000 | ||
CY2020Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-4967000 | |
CY2019Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5546000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-11785000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-11496000 | ||
CY2020Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
3951000 | |
CY2019Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
5426000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
9931000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
10826000 | ||
CY2020Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3592000 | |
CY2019Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4706000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9071000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9733000 | ||
us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | ||
CY2019Q2 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
314000 | |
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
|||
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
7993000 | ||
CY2020Q1 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
221000 | |
CY2019Q1 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
206000 | |
CY2019Q4 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
215000 | |
CY2018Q4 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
272000 | |
CY2020Q2 | us-gaap |
Prepaid Rent
PrepaidRent
|
375000 | |
us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
2330000 | ||
us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
|||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
|||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
18000 | ||
CY2020Q2 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
221000 | |
CY2019Q2 | us-gaap |
Product Warranty Accrual
ProductWarrantyAccrual
|
215000 | |
CY2020Q2 | us-gaap |
Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
|
50000 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
48503 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
48503 | |
CY2020Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
48503 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
48503 | |
CY2020Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2020Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
899000 | |
CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
311000 | |
CY2020Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
765000 | |
CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
722000 | |
CY2020Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3703000 | |
CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4135000 | |
CY2019Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
6000000 | |
CY2020Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4468000 | |
CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4856000 | |
CY2020Q2 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
239000 | |
CY2019Q2 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
219000 | |
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
475000 | ||
us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
219000 | ||
CY2020Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
594000 | |
CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
684000 | |
CY2020Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
19000 | |
CY2019Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
7000 | |
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
29000 | ||
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
|||
CY2020Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
4000 | |
CY2019Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
329000 | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
|||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
569000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
|||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
88000 | ||
CY2020Q2 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
967000 | |
CY2019Q2 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
895000 | |
us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
1934000 | ||
us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
1790000 | ||
CY2020Q2 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
48503000 | |
CY2019Q4 | us-gaap |
Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
|
48503000 | |
CY2020Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q2 | us-gaap |
Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
|
34000 | |
us-gaap |
Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
|
111000 | ||
us-gaap |
Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
|
36000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-9851000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-9706000 | ||
CY2020Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1140000 | |
CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1661000 | |
CY2020Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1297000 | |
CY2019Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1335000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2891000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2749000 | ||
CY2020Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-358186000 | |
CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-348335000 | |
CY2020Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
1466000 | |
CY2019Q2 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2319000 | |
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
3727000 | ||
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
4159000 | ||
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
|||
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
4680000 | ||
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7401000 | |
CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7081000 | |
CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1309.47 | |
CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1291.74 | |
CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
7081000 | |
CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
1291.74 | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
820 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
1705.58 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y32D | ||
CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y295D | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y36D | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y36D | ||
CY2020Q2 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
10808000 | |
CY2019Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
8967000 | |
CY2020Q2 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
1301000 | |
CY2019Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
||
CY2020Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
2654000 | |
CY2019Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
4091000 | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
7040000 | ||
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
8077000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
776000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1009000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P4Y | ||
CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
7004000 | |
CY2020Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1296.85 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
23000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
297000 | ||
us-gaap |
Stock Issued1
StockIssued1
|
|||
us-gaap |
Stock Issued1
StockIssued1
|
2918000 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | ||
CY2019Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
18000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
9000 | |
us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
36000 | ||
us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
27000 | ||
us-gaap |
Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
|
2918000 | ||
CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13279000 | |
CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9920000 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
4408000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7549000 | |
CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
9460000 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6895000 | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its common stock valuation and related stock-based compensation, the valuation of the common stock warrants, the valuation of compound embedded derivatives, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and its reserves for sales returns and warranty costs. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font: inherit;">not</div> readily apparent from other sources. Although these estimates are based on the Company's knowledge of current events and actions it <div style="display: inline; font-style: italic; font: inherit;"> may </div>undertake in the future, actual results <div style="display: inline; font-style: italic; font: inherit;"> may </div>ultimately materially differ from these estimates and assumptions.</div></div></div></div> | ||
CY2020Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27310000 | |
CY2019Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
6377000 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20963000 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
5319000 | ||
us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
0 | ||
us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
0 |